

Product Datasheet

Rezivertinib

Catalog No. **BP-01260** · CAS **1835667-12-3** · Form **free base** · Physical state **solid** · Color **white to off-white** · Version **1.0** · Revision **2026-09-04**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target EGFR	Research area Cancer
-----------------------	--------------------------------

Molecular formula **C₂₇H₃₀N₆O₃**

Molecular weight **486.5655**

STRUCTURE



DESCRIPTION

Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity .

BIOLOGICAL ACTIVITY

In Vitro

Rezivertinib (BPI-7711) selectively inhibits cellular proliferation of EGFR mutations in cell lines: GI50 13.3 nM (PC9, del19), 6.8 nM (HCC827, L858R), 22 nM (NCI-H1975, del19/T790M) and > 1000 nM (A431, EGFR WT).

In Vivo

Rezivertinib (BPI-7711; 6.25-25 mg/kg/day; orally; 14 days) shows significant tumor regression.

Rezivertinib (12.5 mg/kg/day; orally; 14 days) survives an average of 112% longer in H1975-luc human NSCLC mice model.

Rezivertinib (50 mg/kg/day; orally) has anti-tumor efficacy correlated to improved average overall survival of the animals of 115% (28 days vs. 13 days).

SOLUBILITY

soluble in DMSO

REFERENCES

[1]. Misako Nagasaka, et al. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2021 May;16(5):740-763.

[2]. Victoria L. Wilde, et al. Preclinical evidence of BPL-7711 activity in Egfr-mutant non-smallcell lung cancer (NSCLC) in orthotopically implanted human tumorxenografts in the lung and brain.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.